CN117503675A - Preparation method of hydrolyzed placenta caprae seu ovis extract and application of hydrolyzed placenta caprae seu ovis extract in cosmetics - Google Patents
Preparation method of hydrolyzed placenta caprae seu ovis extract and application of hydrolyzed placenta caprae seu ovis extract in cosmetics Download PDFInfo
- Publication number
- CN117503675A CN117503675A CN202311584159.8A CN202311584159A CN117503675A CN 117503675 A CN117503675 A CN 117503675A CN 202311584159 A CN202311584159 A CN 202311584159A CN 117503675 A CN117503675 A CN 117503675A
- Authority
- CN
- China
- Prior art keywords
- hydrolyzed
- mixture
- extract
- skin care
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 53
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000283898 Ovis Species 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 241001494479 Pecora Species 0.000 claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims abstract description 7
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims abstract description 7
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 6
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 6
- 244000068988 Glycine max Species 0.000 claims abstract description 6
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 6
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 6
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 6
- 229960001631 carbomer Drugs 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 6
- 230000004151 fermentation Effects 0.000 claims abstract description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 3
- 239000002244 precipitate Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000005185 salting out Methods 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 102000008186 Collagen Human genes 0.000 abstract description 10
- 108010035532 Collagen Proteins 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 10
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 102000016942 Elastin Human genes 0.000 abstract description 6
- 108010014258 Elastin Proteins 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 229920002549 elastin Polymers 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 210000002950 fibroblast Anatomy 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000002906 medical waste Substances 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 49
- 238000012360 testing method Methods 0.000 description 37
- 230000001815 facial effect Effects 0.000 description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000003278 haem Chemical class 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- -1 superoxide anion free radical Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008728 vascular permeability Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000001521 two-tailed test Methods 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the field of medical, dental or cosmetic formulas, and particularly relates to a preparation method of a hydrolyzed sheep placenta extract and application of the hydrolyzed sheep placenta extract in cosmetics. The hydrolyzed sheep placenta extract is used in cosmetics and comprises glycerol, sodium hyaluronate, hydrolyzed sheep placenta extract, carbomer, bacillus/soybean fermentation product extract, tripeptide-1, hexapeptide-9, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, decapeptide-4, glycoprotein and palmitoyl tripeptide-7. The skin care composition provided by the invention has the effects of removing wrinkles, resisting aging, preserving moisture and resisting oxidation. The component hydrolyzed sheep placenta extract has biological activity, is natural and nontoxic, has the effects of enhancing the activity of fibroblasts and promoting the synthesis of collagen, elastin and mucopolysaccharide. The important raw material adopted in the invention is animal placenta, is discarded medical waste, and improves economic benefit.
Description
Technical Field
The invention belongs to the field of medical, dental or cosmetic formulas, and particularly relates to a preparation method of a hydrolyzed sheep placenta extract and application of the hydrolyzed sheep placenta extract in cosmetics.
Background
With the rapid development of society, the living standard of people is continuously improved, roles played by various skin care products in the life of people are increasingly important, pursuits of people are also higher and higher, the development of the skin care products is more and more advanced, functions and types of the skin care products are more and more various, and the types of the facial masks are important types, and can be divided into tearing-peeling type facial masks, gel type facial masks, cream type facial masks, essential oil facial masks, cotton type facial masks, efficacy type facial masks, facial mask powder type facial masks, freckle-removing facial masks, wrinkle removing facial masks and the like. The action principle of the mask is as follows: the facial mask is a closed environment, the facial temperature is increased, the facial cells are active, the capillary transport is quickened, pores are expanded, wastes and harmful substances in the skin are discharged, moisture keeping factors in the mask essence enter the skin, moisture in the mask permeates into the cuticle of the epidermis, the skin becomes soft, and the skin is natural, bright and elastic.
Placenta is an organ for mass exchange between a mother and a fetus, and is a combination of an embryo and a mother tissue, and is composed of an amniotic membrane, a phylliform chorion and a decidua basal membrane. Placenta is also called placenta, clothes, placenta hominis, and placenta hominis. The placenta contains various effective components for promoting the metabolism and repair of organism tissue cells, and along with the more advanced and more advanced biological pharmaceutical technology, the purer placenta protein can be prepared. Placenta protein, i.e. hydrolyzed extract, has antioxidant, antiaging, moisturizing, and growth promoting effects.
Disclosure of Invention
The invention aims to provide a preparation method of a hydrolyzed sheep placenta extract and application of the hydrolyzed sheep placenta extract in cosmetics, wherein the extract has the effects of repairing skin, resisting wrinkles and tendering skin.
The technical scheme of the invention is as follows:
the preparation method of the hydrolyzed sheep placenta extract comprises the following steps:
(1) Selecting fresh placenta caprae seu ovis, removing placenta and macrovascular, and quick-freezing at-40 to-20deg.C;
(2) Cutting, pulping to 80-100 mesh;
(3) Weighing and then adding 200ml of ammonium sulfate solution with the concentration of 0.15mol/L into every 100g of tissue, and stirring to form slurry;
(4) Regulating the pH of the homogenate to 4.0-5.0 by using inorganic acid, and stirring for 1-3h at the temperature of-8 to 5 ℃;
(5) Centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant,
(6) Regulating pH of supernatant with inorganic base to 5.0-7.0, stirring, adding ammonium sulfate, and salting out until no precipitate appears;
(7) Standing for 20-30 hr, centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant, adding ammonium sulfate, salting out until no precipitate appears, centrifuging at 6000-8000rpm for 45-75min, removing supernatant, and collecting precipitate to obtain hydrolyzed placenta caprae seu ovis extract.
Preferably, the hydrolyzed sheep placenta extract is applied to the field of cosmetics.
The skin care composition comprises the following raw materials in parts by mass:
3-8 parts of glycerol, 0.05-0.1 part of sodium hyaluronate, 0.5-2 parts of hydrolyzed sheep placenta extract, 0.05-0.5 part of carbomer, 0.02-0.2 part of bacillus/soybean fermentation product extract, 0.01-0.2 part of tripeptide, 0.01-0.1 part of hexapeptide-9, 0.01-0.2 part of palmitoyl tripeptide-5, 0.02-0.3 part of palmitoyl pentapeptide-4, 0.01-0.5 part of decapeptide-4, 0.03-0.5 part of glycoprotein and 0.01-0.5 part of palmitoyl tripeptide-7.
Preferably, the preparation also comprises the following raw materials in parts by mass:
10-60 parts of alcohol humectant, 1-10 parts of regulator, 5-15 parts of soothing agent and 1-6 parts of preservative.
Preferably, the alcohol humectant is at least one of butanediol, 1, 3-propanediol and 1, 2-hexanediol.
Preferably, the regulator is at least one of arginine, disodium EDTA, and disodium hydrogen phosphate.
Preferably, the soothing agent is at least one of dipotassium glycyrrhizinate, allantoin, folic acid and glyceryl caprylate.
Preferably, the preservative is at least one of p-hydroxyacetophenone and octanoyl hydroxamic acid.
Preferably, the method comprises the following steps:
(1) Under aseptic condition, adding water into a reaction container, heating, adding carbomer, homogenizing, and making into mixture A;
(2) Heating alcohol humectant in another reactor, adding into the reaction container in step (1), homogenizing, mixing with the mixture A to obtain mixture B,
(3) Cooling the mixture B in the step (2), adding a regulator, a preservative, hyaluronic acid and glycerol into a reaction container, stirring and homogenizing, preparing a mixture C with the mixture B,
(4) Cooling the mixture C in the step (3), adding a soothing agent, hydrolyzed sheep placenta extract, bacillus/soybean fermentation product extract, tripeptide-1, hexapeptide-9, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, decapeptide-4, glycoprotein and palmitoyl tetrapeptide-7 into a reaction container, stirring uniformly, preparing a mixture D with the mixture C, and cooling the mixture D to normal temperature to obtain a finished product.
Preferably, the heating temperature in the step (1) is 80-90 ℃;
the heating temperature in the step (2) is 75-90 ℃;
the temperature in the step (3) is reduced to 65-80 ℃;
and (3) cooling to 40-60 ℃ in the step (4).
The beneficial effects are that:
placenta extract: can scavenge superoxide anion free radical, hydroxyl radical, DPPH free radical, maintain free radical balance, protect cell and DNA from free radical attack, prevent lipid peroxidation and inflammatory reaction, and delay skin aging. The placenta extract contains active ingredients, and can control and regulate skin aging process, protect damaged skin, and delay skin aging. On the whole skin level, the placenta extract can promote proliferation and differentiation of epidermis and dermal cells, thicken skin, repair skin injury, gradually restore normal structure and physiological function, enhance fibroblast activity, promote synthesis of collagen, elastin, mucopolysaccharide and other substances, thicken dermis, restore skin elasticity, improve skin atrophy and water deficiency state, smooth fine wrinkles and keep skin young.
Tripeptide-1: tripeptides have antioxidant property, can promote the generation of collagen, elastin, hyaluronic acid and the like, and have the functions of resisting aging, resisting wrinkle and activating skin; tripeptide-1 promotes the generation of fibronectin, can be used as an activator for tissue remodeling, promotes the degradation of a large amount of collagen aggregates outside the scar, and has the function of wound repair.
Hexapeptide-9: the skin conditioner has the main effects of effectively relieving and inhibiting the contraction and movement of forehead head-up lines, eye fish tail fine lines and peripheral muscles, helping the muscles relax and enabling skin elastic tissues to recover soft and smooth lines. The muscle contraction force can be reduced, the muscle is relaxed, the occurrence of dynamic lines is reduced, and fine lines are eliminated; the collagen elasticity is effectively reorganized, the activity of elastin can be increased, the facial lines are relaxed, and wrinkles are smoothed and relaxed.
Palmitoyl tripeptide-5: promoting skin cell growth, inhibiting oxygen free radical and hydroxyl free radical, promoting synthesis of matrix protein, especially collagen, and possibly increasing production of elastin, hyaluronic acid, glycosaminoglycan and fibronectin. The peptides promote collagen synthesis by increasing stromal cell activity, making the skin appear more elastic and youthful. .
Palmitoyl pentapeptide-4: the palmitoyl pentapeptide-4 has the main functions of moisturizing agent and antioxidant in cosmetics and skin care products, belongs to an anti-aging component, and can stimulate the synthesis of key components of skin matrix, such as collagen, and the like.
Decapeptide-4, a synthetic peptide consisting of arginine, aspartic acid, cysteine, glutamic acid, leucine, methionine and tyrosine, has skin conditioning effect.
Palmitoyl tetrapeptide-7: the skin is compacted by stimulating laminin (laminv) IV, VII collagen, which reduces the production of interleukins and eliminates inflammation. Prevent injury, and prevent wrinkle, relaxation and uneven skin color.
Compared with the prior art, the skin care composition provided by the invention has the effects of removing wrinkles, resisting aging, preserving moisture and resisting oxidation.
The component hydrolyzed sheep placenta extract has biological activity, is natural and nontoxic, has the effects of enhancing the activity of fibroblasts and promoting the synthesis of collagen, elastin and mucopolysaccharide.
The important raw materials adopted in the invention are sheep placenta in animal placenta, and the sheep placenta is subjected to a series of hydrolysis treatment to obtain the treated extract. Sheep placenta is the medical waste that throws away, has improved economic benefits.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
In specific embodiments, steps, material selections, numerical parameters that are not described in detail are all routine selections in the art, or any prior art that is presently disclosed.
Preparation and test of hydrolyzed sheep placenta extract
1. A method for preparing hydrolyzed placenta caprae seu ovis extract comprises:
(1) Selecting fresh placenta caprae seu ovis, removing placenta and macrovascular, and quick-freezing at-40 to-20deg.C;
(2) Cutting, pulping to 80-100 mesh;
(3) Weighing and then adding 200ml of ammonium sulfate solution with the concentration of 0.15mol/L into every 100g of tissue, and stirring to form slurry;
(4) Regulating the pH of the homogenate to 4.0-5.0 by using inorganic acid, and stirring for 1-3h at the temperature of-8 to 5 ℃;
(5) Centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant,
(6) Regulating pH of supernatant with inorganic base to 5.0-7.0, stirring, adding ammonium sulfate, and salting out until no precipitate appears;
(7) Standing for 20-30 hr, centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant, adding ammonium sulfate, salting out until no precipitate appears, centrifuging at 6000-8000rpm for 45-75min, removing supernatant, and collecting precipitate to obtain hydrolyzed placenta caprae seu ovis extract.
2. Testing of hydrolyzed sheep placenta extract for cytotoxicity
(1) Cell inoculation: according to 2.2 x 10 4 Cell/well seeding Density cells were seeded into 96 well plates and incubated overnight in incubator (37 ℃ C., 5% CO) 2 )。
(2) Experimental grouping: the experiment sets a blank control group and an experiment group, 3 cell-free holes are additionally set as zeroing holes, samples in the experiment group are based on the prepared hydrolyzed sheep placenta extract, 5 concentration gradients are set, and 3 compound holes are set under each gradient concentration.
(3) Preparing liquid: according to the experimental design, test substances with different concentrations are prepared by using a basic culture medium.
TABLE 1 test concentration setting table
(4) Administration: taking out the 96-well plate after 24 hours, removing the old culture medium, adding 100 mu L of culture solution into each well of a blank control group, and adding 100 mu L of culture solution containing samples with corresponding concentrations into each well of a sample group; the zeroed group was inoculated without cells and only 100. Mu.L of cell culture medium was added. And after the administration is finished, the culture medium is returned to the incubator for continuous culture.
(5) And (3) detection: after cell culture for 24 hours, the supernatant was discarded and MTT working solution was added. Incubate at 37℃for 4h in the absence of light, after incubation, discard supernatant, add 100. Mu.L DMSO per well, read OD at 490 nm.
(6) Cell relative viability calculation: according to the formula:
(7) Statistical analysis was performed using the SPSS 19.0 statistical software package to descriptive statistics of the measurements of the test area. The change in the analytical value was calculated and the difference between the control group and the sample group. If the test data are normally distributed, adopting an independent T test method to carry out statistical analysis; if the test data are in non-normal distribution, adopting a rank sum test method to carry out statistical analysis. The statistical methods all use a two-tailed test with a test level α=0.05.
The results are shown in Table 2.
Table 2MTT detection results:
3. preparation and testing of skin care compositions
A preparation method of facial mask liquid containing hydrolyzed placenta caprae seu ovis extract comprises the following steps:
(1) Weighing the following raw materials in weight percent in table 3; under aseptic condition, adding water into a reaction container, heating, adding carbomer, homogenizing, and making into mixture A;
(2) Heating alcohol humectant in another reactor, adding into the reaction container in step (1), homogenizing, mixing with the mixture A to obtain mixture B,
(3) Cooling the mixture B in the step (2), adding a regulator, a preservative, hyaluronic acid and glycerol into a reaction container, stirring and homogenizing, preparing a mixture C with the mixture B,
(4) Cooling the mixture C in the step (3), adding a soothing agent, hydrolyzed sheep placenta extract, bacillus/soybean fermentation product extract, tripeptide-1, hexapeptide-9, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, decapeptide-4, glycoprotein and palmitoyl tetrapeptide-7 into a reaction container, stirring uniformly, preparing a mixture D with the mixture C, and cooling the mixture D to normal temperature to obtain a finished product.
Table 3 raw material ratio of mask liquid:
in table 3, the blank indicates that no corresponding component was added.
4. Stability test:
1) Heat resistance test: the temperature of the incubator was adjusted to 40 ℃, three samples of the 4 examples prepared above were taken and placed in an aluminum film mask bag, the sample loading amount was 30 ml/bag, the samples were placed in the incubator after being sealed, and the samples were taken out after three months, and the samples were returned to room temperature and observed for appearance changes.
2) Cold resistance test: the temperature of the constant temperature incubator is regulated to-10 ℃, three prepared 4 examples are taken and arranged in an aluminum film mask bag in each example, the sample loading amount is 30 ml/bag, the bag is placed in the constant temperature incubator after being sealed, and the incubator is taken out after three months, returns to the room temperature and observes the appearance change.
3) And (3) normal temperature test: three of the 4 prepared examples are taken and arranged in an aluminum film mask bag in each example, the sample filling amount is 230 ml/bag, and after the bag is sealed and placed for 6 months at normal temperature, the appearance change of the essence is observed.
No phenomena such as precipitation and precipitation are observed in the heat resistance test, the cold resistance test and the normal temperature test, and the original appearance is maintained.
5. Component testing:
the following indexes were tested on the samples subjected to the stability test according to 2022 cosmetic safety technical Specification, as shown in Table 4.
Table 4 test results:
6. human skin patch test:
the obtained 4 groups of examples are referred to the human skin patch experiments in 2022 cosmetic safety technical Specification.
Skin reactions were observed as standard at 30min (after the disappearance of the indentations), 24h and 48h, respectively, and the observations were recorded, see table 5.
Table 5 human safety test results:
7. human subjective feeling test:
for the obtained 4 groups of examples, selecting women aged 30-50 years as experimental subjects for clinical test, wherein the total number of the experiments is 40, the women are used for 1 month per night continuously, the examples are soaked by facial mask paper, the facial mask paper is applied to the face of a user, and the residues are washed by clean water after 15 minutes of each use; the elasticity, wrinkle reduction amount and moisture retention of facial skin were evaluated by the subjects during the experiment, and the experimental results are shown in table 6 below.
Table 6 results of subjective human experience test:
8. human body instrument test:
the effect of the examples was evaluated scientifically by instrumental measurements.
(1) Preparation before experiments
1. A subject
Inclusion criteria:
a) Healthy volunteers 18 to 60 years old;
b) And the score of the lactic acid stinging test is 3 points or more.
c) Voluntary participation and signing of informed consent;
d) The specified content can be completed according to the test requirement.
Exclusion criteria:
a) Antihistamines used in the last week or immunosuppressants used in the last month;
b) Any anti-inflammatory agent is applied to the tested part in the last two months;
c) A subject suffering from a clinically unhealed inflammatory skin condition;
d) Insulin dependent diabetes mellitus patients;
e) Asthma or other chronic respiratory disease patients undergoing treatment;
f) Patients who received anti-cancer chemotherapy for nearly six months;
g) Patients with immunodeficiency or autoimmune disease;
h) Women in lactation or gestation;
i) Bilateral mastectomy and bilateral axillary lymphadenectomy;
j) Participate in other clinical trial researchers;
k) Highly sensitive body constitution;
1) The face has large-area marks, scratches, white spots, pigmented nevi, keloids and other skin characterizations affecting the test;
m) non-voluntary participants or those who cannot fulfill the prescribed content as required by the trial.
The number of people to be tested is set:
the number of volunteers is guaranteed to be more than 10, and the subjects mainly move indoors and are prevented from being exposed to light and high temperature and high cold environments for a long time.
(2) Test scheme and test method:
the scheme is as follows:
the effects of moisturization, soothing, and rejuvenation were evaluated by screening 10 eastern human skin subjects 18-56 years old, who were reddish in face sensitivity and scored 3 minutes or more in the lactic acid stinging test, using the product of example 1 above for 4 weeks, by skin moisture content tester, transdermal water loss tester, skin melanin and heme tester probe, facial image analyzer VISIA 7, and lactic acid stinging test.
Test environment:
laboratory temperature 21±1 ℃; relative humidity 50% ± 10%.
The evaluation method comprises the following steps:
the test adopts a double-blind method and a self front-back comparison method, the test period is 4 weeks, the skin data acquisition times are 3 times, and the skin data acquisition times are 0W, 2W and 4W respectively. Qualified subjects were screened as required, and upon the first visit of the volunteer, volunteer informed consent was signed, data were collected for 0 weeks, and samples were dispensed. When volunteers visit each time, the volunteers use the appointed clean face to wash the face, then the volunteers apply the face to the face of the users, and the residues are washed by clean water after 15 minutes of each use; the acquisition of skin images and data is started.
Test instrument:
skin moisture content tester (Corneometer CM825, CK, germany): the moisture content of the human skin cuticle is measured by adopting a capacitance method.
Percutaneous moisture loss tester (Tewameter TM300; CK, germany): the water vapor pressure gradient at different points of the epidermis formed by the water loss of the angle layer is measured by two groups of sensors with different temperatures and humidity, and the water content evaporated through the epidermis is measured.
Skin melanin and heme test probe (Mexameter MX18, germany C & K): the higher the heme content, the enhanced vascular permeability, representing a redder skin tone; the lower the heme content, the reduced vascular permeability, representing reduced redness of the skin.
Skin observation and evaluation:
with the help of a facial image analyzer VISIA 7 (Canfield, U.S.A.), the instrument uses 3 different light sources to take facial images, and can visually observe the change of facial skin states.
The test indexes are as follows:
skin moisture content (MMV value): MMV values characterize skin moisture, with greater MMV values indicating higher stratum corneum moisture content.
Percutaneous moisture loss (TEWL value): TEWL values are important parameters for evaluating skin barrier function, with smaller values leading to less skin loss of water through the skin.
Skin heme content (EI value): the higher the heme content, the enhanced vascular permeability, representing a redder skin tone; the lower the heme content, the reduced vascular permeability, representing reduced redness of the skin.
Lactic acid stinging score: the degree of stimulation of 10% lactic acid to the subject is shown, and the smaller the value, the lower the degree of feeling of the subject to lactic acid stimulation.
Data analysis:
1. the calculation formula is as follows:
average value of,/> ，
，
，
。
2. Statistical analysis method
The data were analyzed using SPSS 19.0 data analysis software. And (3) carrying out normal distribution and variance alignment test on each parameter before statistical analysis, and carrying out paired t-test analysis when the data shows normal distribution. When the data exhibits a non-normal distribution, a pairing rank and test analysis is performed. The statistical method uses a two-tailed test with a test level of α=0.05.
Compare with initial value 0W, "+": p <0.05, representing significant differences, "x": p <0.01, ", x": p <0.001, representing a very significant difference.
(3) Results and analysis
1. Skin moisture MMV values results are shown in table 7.
Table 7:
2. the results of the skin transcutaneous water loss TEWL values are shown in table 8.
Table 8:
3. skin heme EI value results are shown in Table 9.
Table 9:
4. lactic acid stimulation scoring results are shown in table 10.
Table 10:
the foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (10)
1. The preparation method of the hydrolyzed sheep placenta extract is characterized by comprising the following steps of:
(1) Selecting fresh placenta caprae seu ovis, removing placenta and macrovascular, and quick-freezing at-40 to-20deg.C;
(2) Cutting, pulping to 80-100 mesh;
(3) Weighing and then adding 200ml of ammonium sulfate solution with the concentration of 0.15mol/L into every 100g of tissue, and stirring to form slurry;
(4) Regulating the pH of the homogenate to 4.0-5.0 by using inorganic acid, and stirring for 1-3h at the temperature of-8 to 5 ℃;
(5) Centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant,
(6) Regulating pH of supernatant with inorganic base to 5.0-7.0, stirring, adding ammonium sulfate, and salting out until no precipitate appears;
(7) Standing for 20-30 hr, centrifuging at 6000-8000rpm for 45-75min, removing precipitate, collecting supernatant, adding ammonium sulfate, salting out until no precipitate appears, centrifuging at 6000-8000rpm for 45-75min, removing supernatant, and collecting precipitate to obtain hydrolyzed placenta caprae seu ovis extract.
2. Use of the hydrolyzed sheep placenta extract of claim 1 in the cosmetic field.
3. The skin care composition is characterized by comprising the following raw materials in parts by mass:
3-8 parts of glycerol, 0.05-0.1 part of sodium hyaluronate, 0.5-2 parts of hydrolyzed sheep placenta extract, 0.05-0.5 part of carbomer, 0.02-0.2 part of bacillus/soybean fermentation product extract, 0.01-0.2 part of tripeptide, 0.01-0.1 part of hexapeptide-9, 0.01-0.2 part of palmitoyl tripeptide-5, 0.02-0.3 part of palmitoyl pentapeptide-4, 0.01-0.5 part of decapeptide-4, 0.03-0.5 part of glycoprotein and 0.01-0.5 part of palmitoyl tripeptide-7.
4. A skin care composition according to claim 3, characterized in that it further comprises the following raw materials, in parts by mass:
10-60 parts of alcohol humectant, 1-10 parts of regulator, 5-15 parts of soothing agent and 1-6 parts of preservative.
5. The skin care composition of claim 4 wherein said alcohol humectant is at least one of butylene glycol, 1, 3-propanediol, and 1, 2-hexanediol.
6. The skin care composition of claim 4 wherein the modulator is at least one of arginine, disodium EDTA, and disodium hydrogen phosphate.
7. The skin care composition of claim 4 wherein the soothing agent is at least one of dipotassium glycyrrhizinate, allantoin, folic acid and glyceryl caprylate.
8. The skin care composition according to claim 4 wherein said preservative is at least one of p-hydroxyacetophenone and octanoyl hydroxamic acid.
9. A method of preparing a skin care composition according to any one of claims 4 to 8, comprising the steps of:
(1) Under aseptic condition, adding water into a reaction container, heating, adding carbomer, homogenizing, and making into mixture A;
(2) Heating alcohol humectant in another reactor, adding into the reaction container in step (1), homogenizing, mixing with the mixture A to obtain mixture B,
(3) Cooling the mixture B in the step (2), adding a regulator, a preservative, hyaluronic acid and glycerol into a reaction container, stirring and homogenizing, preparing a mixture C with the mixture B,
(4) Cooling the mixture C in the step (3), adding a soothing agent, hydrolyzed sheep placenta extract, bacillus/soybean fermentation product extract, tripeptide-1, hexapeptide-9, palmitoyl tripeptide-5, palmitoyl pentapeptide-4, decapeptide-4, glycoprotein and palmitoyl tetrapeptide-7 into a reaction container, stirring uniformly, preparing a mixture D with the mixture C, and cooling the mixture D to normal temperature to obtain a finished product.
10. A method of preparing a skin care composition according to claim 9, wherein,
the heating temperature in the step (1) is 80-90 ℃;
the heating temperature in the step (2) is 75-90 ℃;
the temperature in the step (3) is reduced to 65-80 ℃;
and (3) cooling to 40-60 ℃ in the step (4).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310285843X | 2023-03-22 | ||
| CN202310285843.XA CN116284211A (en) | 2023-03-22 | 2023-03-22 | Preparation method of placenta protein and application of placenta protein in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117503675A true CN117503675A (en) | 2024-02-06 |
Family
ID=86826961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310285843.XA Pending CN116284211A (en) | 2023-03-22 | 2023-03-22 | Preparation method of placenta protein and application of placenta protein in cosmetics |
| CN202311584159.8A Pending CN117503675A (en) | 2023-03-22 | 2023-11-25 | Preparation method of hydrolyzed placenta caprae seu ovis extract and application of hydrolyzed placenta caprae seu ovis extract in cosmetics |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310285843.XA Pending CN116284211A (en) | 2023-03-22 | 2023-03-22 | Preparation method of placenta protein and application of placenta protein in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116284211A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103525890A (en) * | 2013-09-27 | 2014-01-22 | 四川大学 | Preparation method of human placenta collagen |
| CN109627282A (en) * | 2018-11-12 | 2019-04-16 | 吉林大学 | Active doe placenta albumen and its extracting method and application |
| CN110585111A (en) * | 2019-10-16 | 2019-12-20 | 广州雅纯化妆品制造有限公司 | Anti-aging cosmetic additive and preparation method thereof |
-
2023
- 2023-03-22 CN CN202310285843.XA patent/CN116284211A/en active Pending
- 2023-11-25 CN CN202311584159.8A patent/CN117503675A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103525890A (en) * | 2013-09-27 | 2014-01-22 | 四川大学 | Preparation method of human placenta collagen |
| CN109627282A (en) * | 2018-11-12 | 2019-04-16 | 吉林大学 | Active doe placenta albumen and its extracting method and application |
| CN110585111A (en) * | 2019-10-16 | 2019-12-20 | 广州雅纯化妆品制造有限公司 | Anti-aging cosmetic additive and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116284211A (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110013447B (en) | Cream for removing striae gravidarum and preparation method thereof | |
| CN108379110B (en) | Skin care composition, skin care cream and preparation method thereof | |
| CN111481460A (en) | Polypeptide anti-wrinkle anti-aging essence and preparation method thereof | |
| CN115137665A (en) | Composition with long-acting moisturizing and relieving effects and application thereof | |
| CN110302091A (en) | A kind of anti aging effect composition of niacinamide-containing adenine-dinucleotide and its preparation method and application | |
| CN113332227A (en) | Soothing and repairing composition and application thereof in cosmetics | |
| CN104254318A (en) | Cosmetic composition containing the slime of snails fed with red ginseng and method for manufacturing same | |
| KR101098400B1 (en) | A method for mucus of acusta despecta sieboldiana feed red ginseng and cosmetic composition containing thereof | |
| CN111265454B (en) | Moisture-preserving and water-replenishing anti-aging cosmetic composition | |
| CN114306165A (en) | Moisturizing composition and preparation method thereof | |
| CN116077410A (en) | Composition and preparation with skin barrier repairing function, and preparation and application thereof | |
| CN113749974A (en) | Acne-clearing repairing mask and preparation method thereof | |
| CN114903810B (en) | Peptide-containing anti-wrinkle composition and application thereof | |
| CN113940909B (en) | Composition for regulating circadian rhythm and application thereof | |
| CN114099388B (en) | Anti-wrinkle composition and preparation method and application thereof | |
| CN117503675A (en) | Preparation method of hydrolyzed placenta caprae seu ovis extract and application of hydrolyzed placenta caprae seu ovis extract in cosmetics | |
| CN109330917B (en) | Essential oil composition with whitening, anti-aging and moisturizing effects and application thereof | |
| CN112933024A (en) | Repair face cream containing industrial hemp extract and preparation method thereof | |
| CN110327268A (en) | Composition and its application in the personal care product of preparation anti-aging | |
| CN111265451A (en) | Protein rejuvenation and repairing freeze-dried mask and preparation method thereof | |
| CN115969759B (en) | Photoprotective plant extract compositions and uses thereof | |
| CN114886794B (en) | Composition with anti-inflammatory and antioxidant effects and application thereof | |
| CN117357460B (en) | Sensitivity-relieving special care essence for moderately severe sensitive muscles and preparation method thereof | |
| CN116617129B (en) | Composition with skin repairing effect and skin care product | |
| CN116270349B (en) | Composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |